
Opinion|Videos|March 25, 2025
Adverse Events Monitoring and Management in BPDCN Treatment
Author(s)Marlise R. Luskin, MD, MSCE
An expert discusses how monitoring capillary leakage syndrome (CLS) requires vigilant assessment of fluid balance, hemodynamics, and biomarkers. Academic settings may have advanced resources, whereas community settings rely on standardized protocols. Key adverse effects include hypotension, edema, and organ dysfunction. Management includes fluid resuscitation, vasopressors, and close monitoring.
Advertisement
Video content above is prompted by the following:
- What protocols/strategies do you implement to monitor CLS?
- What are specific considerations (ie, academic vs community setting)?
- What other adverse effects are critical to monitor?
- What strategies can be implemented to mitigate/manage them?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5


























